Katarina Luptakova
Chief Tech/Sci/R&D Officer bei XILIO THERAPEUTICS, INC.
Vermögen: - $ am 31.03.2024
Profil
Katarina Luptakova is currently the Chief Medical Officer at Xilio Therapeutics, Inc. She previously worked as the Senior Medical Director at Tesaro, Inc. and as the Vice President-Clinical Development at Constellation Pharmaceuticals, Inc. She holds a doctorate degree from the University of Commenius.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
XILIO THERAPEUTICS INC
-.--% | 01.01.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Katarina Luptakova
| Unternehmen | Position | Beginn |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.10.2022 |
Ehemalige bekannte Positionen von Katarina Luptakova
| Unternehmen | Position | Ende |
|---|---|---|
| TESARO INC | Chief Tech/Sci/R&D Officer | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Katarina Luptakova
| University of Commenius | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
